an interaction between gemfibrozil and repaglinide may occur when these drugs are administered concomitantly - in the situation the blood glucose-lowering effect of repaglinide may be markedly enhanced and prolonged. In light of this interaction, co-administration of gemfibrozil and repaglinide is contraindicated
any change in repaglinide pharmacokinetics as a result of co-administration of gemfibrozil is likely to via inhibition of cytochrome P450 2C8. Thus other inhibitors of this enzyme e.g. trimethoprim, may also, if co-administered, enhance of effect of repaglinide
it is not expected that other lipid-lowering agents will have a similar interaction with repaglinide
Reference:
Current Problems in Pharmacovigilance (2003), 29, 6.
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.